{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:45:55Z","timestamp":1740181555582,"version":"3.37.3"},"reference-count":31,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Case Reports"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jaccas.2024.102829","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T23:26:13Z","timestamp":1733354773000},"page":"102829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SGLT2 Inhibitor for Cardiac Protection in a Patient With Osimertinib-Responsive Advanced EGFR-Positive Lung Cancer"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2247-6942","authenticated-orcid":false,"given":"Aditya V.","family":"Belamkar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwan","family":"Mounayar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suparna C.","family":"Clasen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jaccas.2024.102829_bib1","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccas.2024.102829_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109080","article-title":"The impact of SGLT2 inhibitors on inflammation: a systematic review and meta-analysis of studies in rodents","volume":"111","author":"Theofilis","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaccas.2024.102829_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121207","article-title":"Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis","volume":"312","author":"Min","year":"2023","journal-title":"Life Sci"},{"issue":"8","key":"10.1016\/j.jaccas.2024.102829_bib4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","article-title":"Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines","volume":"10","author":"Gongora","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.jaccas.2024.102829_bib5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaccao.2023.03.011","article-title":"The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer","volume":"5","author":"Abdel-Qadir","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"4","key":"10.1016\/j.jaccas.2024.102829_bib6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/JCO.20.01171","article-title":"Cardiac safety of osimertinib: a review of data","volume":"39","author":"Ewer","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.jaccas.2024.102829_bib7","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.jtho.2021.07.030","article-title":"Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC","volume":"16","author":"Waliany","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"2","key":"10.1016\/j.jaccas.2024.102829_bib8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-induced cardiotoxicity: a retrospective review of the FDA Adverse Events Reporting System (FAERS)","volume":"1","author":"Anand","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccas.2024.102829_bib9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.lungcan.2020.10.021","article-title":"Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction","volume":"153","author":"Kunimasa","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jaccas.2024.102829_bib10","article-title":"Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jaccas.2024.102829_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jaccao.2020.01.003","article-title":"Heart failure associated with the epidermal growth factor receptor inhibitor osimertinib","volume":"2","author":"Piper-Vallillo","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"16","key":"10.1016\/j.jaccas.2024.102829_bib12","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.2169\/internalmedicine.8344-16","article-title":"Congestive heart failure during osimertinib treatment for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)","volume":"56","author":"Watanabe","year":"2017","journal-title":"Intern Med"},{"issue":"8","key":"10.1016\/j.jaccas.2024.102829_bib13","article-title":"Heart failure with reduced ejection fraction caused by osimertinib in a patient with lung cancer: a case report and literature review","volume":"14","author":"Okuzumi","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jaccas.2024.102829_bib14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.26502\/fccm.92920263","article-title":"Osimertinib- cardiac dysfunction with prolonged QTc interval: a case report","volume":"6","author":"Medepalli","year":"2022","journal-title":"Cardiol Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.jaccas.2024.102829_bib15","first-page":"52","article-title":"Osimertinib-induced cardiac dysfunction in EGFR-mutated lung cancer: a case series of five patients","volume":"6","author":"Reale","year":"2018","journal-title":"Am J Cancer Case Rep"},{"issue":"4","key":"10.1016\/j.jaccas.2024.102829_bib16","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jaccas.2019.12.038","article-title":"Osimertinib-induced cardiomyopathy","volume":"2","author":"Patel","year":"2020","journal-title":"JACC Case Rep"},{"issue":"1","key":"10.1016\/j.jaccas.2024.102829_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2020.02.003","article-title":"Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with osimertinib","volume":"2","author":"Kunimasa","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.jaccas.2024.102829_bib18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s13691-020-00450-2","article-title":"Osimertinib-induced cardiac failure with QT prolongation and torsade de pointes in a patient with advanced pulmonary adenocarcinoma","volume":"10","author":"Ikebe","year":"2021","journal-title":"Int Cancer Conf J"},{"issue":"2","key":"10.1016\/j.jaccas.2024.102829_bib19","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/medicina58020312","article-title":"Successful management of osimertinib-induced heart failure","volume":"58","author":"Fukuo","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"10.1016\/j.jaccas.2024.102829_bib20","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1177\/10781552211073823","article-title":"Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma","volume":"28","author":"Bardaro","year":"2022","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"4","key":"10.1016\/j.jaccas.2024.102829_bib21","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1177\/10781552221143787","article-title":"Possible heart failure caused by osimertinib in a lung cancer patient","volume":"29","author":"Ruiz-Briones","year":"2023","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"4","key":"10.1016\/j.jaccas.2024.102829_bib22","first-page":"609","article-title":"[A Case of Significant Ejection Fraction Reduction and Heart Failure Induced by Osimertinib]","volume":"47","author":"Ito","year":"2020","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.jaccas.2024.102829_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/10781552231164301","article-title":"Multiple cardiotoxicities during osimertinib therapy","author":"Kobat","year":"2023","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.jaccas.2024.102829_bib24","article-title":"Aumolertinib effectively reduces clinical symptoms of an EGFR L858R-mutant non-small cell lung cancer case coupled with osimertinib-induced cardiotoxicity: case report and review","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"10.1016\/j.jaccas.2024.102829_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.6279","article-title":"Reoccurrence of takotsubo cardiomyopathy induced by osimertinib: a case report","volume":"10","author":"Fukuda","year":"2022","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jaccas.2024.102829_bib26","article-title":"Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review","volume":"6","author":"Teran Brage","year":"2022","journal-title":"Curr Probl Cancer Case Rep"},{"issue":"39","key":"10.1016\/j.jaccas.2024.102829_bib27","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000022301","article-title":"Osimertinib induced cardiomyopathy: a case report","volume":"99","author":"Shinomiya","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"10.1016\/j.jaccas.2024.102829_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2023-255245","article-title":"Severe cardiotoxicity induced by osimertinib in a patient with EGFR-mutated adenocarcinoma of the lung","volume":"16","author":"Tanaka","year":"2023","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.jaccas.2024.102829_bib29","first-page":"38","article-title":"Osimertinib-induced biventricular cardiomyopathy with abnormal cardiac MRI findings: a case report","volume":"9","author":"Patel","year":"2023","journal-title":"Cardiooncology"},{"issue":"1","key":"10.1016\/j.jaccas.2024.102829_bib30","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1159\/000533826","article-title":"Successful rechallenge with osimertinib following osimertinib-induced ventricular tachycardia: a case report","volume":"16","author":"Saito","year":"2023","journal-title":"Case Rep Oncol"},{"issue":"6","key":"10.1016\/j.jaccas.2024.102829_bib31","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/CAD.0000000000001595","article-title":"Delayed cardiotoxicity following osimertinib therapy in non-small cell lung cancer: a unique case report","volume":"35","author":"Xu","year":"2024","journal-title":"Anticancer Drugs"}],"container-title":["JACC: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084924008921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084924008921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:12:56Z","timestamp":1734135176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666084924008921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":31,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2666084924008921"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccas.2024.102829","relation":{},"ISSN":["2666-0849"],"issn-type":[{"type":"print","value":"2666-0849"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 Inhibitor for Cardiac Protection in a Patient With Osimertinib-Responsive Advanced EGFR-Positive Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"JACC: Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2024.102829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102829"}}